Clearside BioMedical. has filed a patent for a method involving retinal injection. The process includes inserting a hollow conduit into the eye, confirming its position, extending it to the injection region, and delivering medication. This innovation aims to improve the precision and effectiveness of ocular drug delivery. GlobalData’s report on Clearside BioMedical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Clearside BioMedical Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Clearside BioMedical, Wearable drug delivery devices was a key innovation area identified from patents. Clearside BioMedical's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Method for retinal injection using medical injector

Source: United States Patent and Trademark Office (USPTO). Credit: Clearside BioMedical Inc

A recently filed patent (Publication Number: US20230363941A1) outlines a method and apparatus for delivering medication into the eye of a patient. The method involves inserting a hollow conduit into the eye until it reaches a specific reference location, confirming its positioning, and then extending it further into the injection region of the eye to convey the medicament. The confirmation of the conduit's placement can be done by measuring pressure or light emissivity gradient within the eye. Additionally, the apparatus described in the patent includes a housing with an actuator, a hollow conduit, a measurement device, and an injection controller to deliver the medication effectively.

Furthermore, the patent details a method that involves inserting a hollow conduit and a catheter into the eye to deliver medication into a specific region between the sclera and the retina. By inflating a balloon attached to the catheter, a space is created or expanded within the region, allowing for the injection of the medicament. The method also includes steps to ensure the conduit is in the correct position within the eye, with the option to hydrodissect the sclera and choroid for separation. The patent also introduces a method using optical fiber and a detector to identify the conduit's location in the eye, enabling precise delivery of the medication into the target injection region. The use of Optical Coherence Tomography (OCT) is also mentioned as part of the measurement device in the apparatus.

To know more about GlobalData’s detailed insights on Clearside BioMedical, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies